Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM-UKM)
Bandar Tun Razak, Kuala Lumpur, 56000, Malaysia
NCT Number: NCT05016011
In terms of the surgical treatment of the cartilage injury, various techniques and ways are created to repair or regenerate articular surface of synovial joint following traumatic damage or degeneration of the cartilage. The option for surgical treatments based on the size and depth of the cartilage knee injury may include knee debridement, radiofrequency, drilling, microfracture, mosaicplasty, allogenic osteochondral transplantation and autologous chondrocyte transplantation. The first two techniques mentioned have been used in treating the cartilage knee injury involving the partial defects meanwhile the latter techniques have been used for Grade III and IV cartilage defects based on ICRS. However, most of the surgical options up only provide more of Type I collagen rather than Type II collagen. The available treatments are more symptomatic rather than preventive or regenerative. Stem cell has big potential in this area where it has ability to differentiate to cartilage. As allogeneic umbilical cord blood MSCs are readily available and can be administered immediately, this study therefore aims to prove the efficacy of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) for treating large defects knee injury.
The study is a prospective, randomized controlled, open label, phase IIb clinical trial, involving 50 patients with large defects of cartilage injury for follow-up duration of 24 months. Patients will be assigned into 2 arms; Arm A - 25 subjects will receive Chondrocell-EX (UC-MSCs) and Arm B - 25 subject will receive marrow cellution. All patients will undergo debridement prior to receiving their assigned treatment. The patients will be assessed on KOOS, IKDC, VAS and MRI.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Bandar Tun Razak, Kuala Lumpur, 56000, Malaysia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Human umbilical cord-derived mesenchymal stem cells
Other names: Chondrocell-EX
Patients will undergo marrow cellution surgical procedure.
Time frame: 24 months
Time frame: 24 months
Time frame: 24 months
Time frame: 24 months
Time frame: 12 months
IHC staining for generated cartilage
Cytopeutics Sdn. Bhd.
Industry
Phase IIb Study Assessing the Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells for Knee Cartilage Injury
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07364578
Arthritis, Joint Diseases
Banī Suwayf, Egypt
View Trial DetailsNCT03895489
Arthritis, Joint Diseases
Edmonton, Alberta, Canada
View Trial DetailsNCT06693648
Arthritis, Joint Diseases
Thousand Oaks, California, United States
View Trial DetailsNCT06522906
Arthritis, Behavior
Tucson, Arizona, United States
View Trial Details